Should Investors Turn Their Attention to DaVita (NYSE:DVA)? Raymond James Upgrades Shares

DaVita Inc. (NYSE:DVA) Logo

Investors sentiment decreased to 0.85 in 2018 Q2. Its down 0.05, from 0.9 in 2018Q1. It is negative, as 42 investors sold DaVita Inc. shares while 156 reduced holdings. 50 funds opened positions while 119 raised stakes. 142.23 million shares or 2.37% less from 145.68 million shares in 2018Q1 were reported.

Northwestern Mutual Wealth Com owns 0% invested in DaVita Inc. (NYSE:DVA) for 1,353 shares. Partner Invest Mgmt Lp stated it has 1.13% of its portfolio in DaVita Inc. (NYSE:DVA). Denali Ltd reported 5,900 shares stake. Point72 Asset Mgmt L P invested 0.03% in DaVita Inc. (NYSE:DVA). Sumitomo Mitsui Tru Holdg Inc stated it has 477,191 shares or 0.04% of all its holdings. Tci Wealth Advsrs invested in 4 shares or 0% of the stock. Brown Advisory Inc reported 0.01% stake. Proshare Limited Liability Corporation invested in 0.01% or 21,382 shares. Citadel Advsr Ltd Liability Corporation stated it has 0% of its portfolio in DaVita Inc. (NYSE:DVA). Fdx Advsrs Incorporated reported 15,593 shares or 0.04% of all its holdings. The New York-based Neuberger Berman Grp Limited Liability Corporation has invested 0.1% in DaVita Inc. (NYSE:DVA). Utah Retirement invested in 25,018 shares or 0.04% of the stock. State Of Wisconsin Inv Board, Wisconsin-based fund reported 106,787 shares. Mufg Americas Hldg owns 0% invested in DaVita Inc. (NYSE:DVA) for 106 shares. Calamos Advsrs Ltd Llc holds 45,372 shares or 0.02% of its portfolio.

Since June 7, 2018, it had 0 insider purchases, and 1 sale for $86,918 activity.

DaVita (NYSE:DVA) Stock Upgrade

Raymond James raised the rating on DaVita (NYSE:DVA) shares to a “Buy”. This change in their rating was just issued to clients in analysts report earlier today.

DaVita Inc. (NYSE:DVA) Ratings Coverage

Among 5 analysts covering DaVita (NYSE:DVA), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. DaVita has $78 highest and $64 lowest target. $70.67’s average target is 6.98% above currents $66.06 stock price. DaVita had 6 analyst reports since June 6, 2018 according to SRatingsIntel. The rating was upgraded by JP Morgan on Thursday, September 13 to “Neutral”. RBC Capital Markets maintained DaVita Inc. (NYSE:DVA) rating on Thursday, November 8. RBC Capital Markets has “Sector Perform” rating and $78 target. The rating was upgraded by Raymond James to “Outperform” on Wednesday, November 28. The rating was downgraded by Raymond James to “Market Perform” on Thursday, November 8.

The stock increased 0.61% or $0.4 during the last trading session, reaching $66.06. About 1.70M shares traded. DaVita Inc. (NYSE:DVA) has risen 12.06% since December 2, 2017 and is uptrending. It has underperformed by 3.56% the S&P500.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease . The company has market cap of $10.97 billion. It operates through two divisions, DaVita Kidney Care and DaVita Medical Group. It has a 19.08 P/E ratio. The firm operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.

More notable recent DaVita Inc. (NYSE:DVA) news were published by: which released: “Benzinga’s Top Upgrades, Downgrades For November 28, 2018 – Benzinga” on November 28, 2018, also with their article: “APC, NBL among premarket gainers – Seeking Alpha” published on November 07, 2018, published: “Ray Dalio’s Top 5 Buys in 3rd Quarter –” on November 13, 2018. More interesting news about DaVita Inc. (NYSE:DVA) were released by: and their article: “Warren Buffett’s DaVita Pares Early Gains on Lower Kidney Care EBIT Guidance –” published on November 07, 2018 as well as‘s news article titled: “Election Day ballot measures send ripples, potential headaches throughout Corporate America – The Business Journals” with publication date: November 07, 2018.

DaVita Inc. (NYSE:DVA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.